Search
AOD9604
go.drugbank.com/drugs/DB06388ExperimentalAOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalFDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Raltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalFood and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Tafluprost
go.drugbank.com/drugs/DB08819ApprovedTafluprost was approved for use in the U.S. on February 10, 2012.
Tryptophan
go.drugbank.com/drugs/DB00150ApprovedInvestigationalNutraceuticalWithdrawnAn essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid)...
Mixtures: TRAVASOL SOLUCION 8.5% CON ELECTROLITOSMeplazumab
go.drugbank.com/drugs/DB16465InvestigationalMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalOur team is working on the full update, which will be available soon. [L54673,L54668]
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Encainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnThe manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.